Zilovertamab

DB18403InvestigationalProtein Based Therapies

Zilovertamab: Overview.

Mechanism: Pharmacologically active on Inactive tyrosine-protein kinase transmembrane receptor ROR1
Curator reviewed
Also known as: Cirmtuzumab · Immunoglobulin g1, anti-(human receptor tyrosine kinase ror-1) (human-mus musculus monoclonal uc-961 .gamma.1-chain), disulfide with human-mus musculus monoclonal uc-961 .kappa.-chain, dimer
Code names: UC-961

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zilovertamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.